利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

126 条记录 (耗时 0.047 秒)

    Methods and compositions related to modulating the extracellular stem cell environment
    1.
    发明申请
    Methods and compositions related to modulating the extracellular stem cell environment 审中-公开
    与调节细胞外干细胞环境相关的方法和组合

    公开(公告)号：US20070020243A1

    公开(公告)日：2007-01-25

    申请号：US11332766

    申请日：2006-01-12

    申请人： Shiladitya Sengupta ,  Ram Sasisekharan ,  Nishla Keiser ,  David Eavarone ,  Tanyel Kiziltepe Bilgicer ,  Aarthi Chandrasekaran ,  David Berry ,  Kristine Holley

    发明人： Shiladitya Sengupta ,  Ram Sasisekharan ,  Nishla Keiser ,  David Eavarone ,  Tanyel Kiziltepe Bilgicer ,  Aarthi Chandrasekaran ,  David Berry ,  Kristine Holley

    IPC分类号： A61K35/12 ,  C12N5/08 ,  C12N5/06

    CPC分类号： A61K31/726 ,  A61K31/727 ,  A61K38/47 ,  C12N5/0606 ,  C12N5/0691 ,  C12N2501/70 ,  C12N2506/02

    摘要： This invention relates, in part, to methods and compositions that modulate the stem cell environment. More specifically, the invention relates, in part, to methods and compositions for modulating stem cell differentiation. Such modulation, in some aspects of the invention, is accomplished by agents that modulate glycosaminoglycans in the stem cell microenvironment (i.e., at or on the cell surface and/or in the extracellular matrix). Therefore, methods and compositions are provide for modulating glycosaminoglycan moieties, e.g., heparan sulfate glycosaminoglycan (HSGAG) moieties, in the microenvironment of stem cells. Methods and compositions for promoting or inhibiting embryonic stem cell differentiation (e.g., differentiation into endothelial cells) are also provided. This invention also relates, therefore, in part, to cell populations (e.g., endothelial cell populations or impoverished endothelial cell populations) that can be produced with the methods and compositions provided. Furthermore, the invention relates, in part, to tissues, and uses thereof, formed by the methods and compositions provided. Moreover, the invention also relates, in part, to methods of treatment using the methods and compositions provided.

    摘要翻译： 本发明部分涉及调节干细胞环境的方法和组合物。 更具体地，本发明部分涉及用于调节干细胞分化的方法和组合物。 在本发明的某些方面，这种调节是通过调节干细胞微环境中的糖胺聚糖（即在细胞表面上和/或细胞外基质中）上的调节剂来完成的。 因此，提供了在干细胞的微环境中调节糖胺聚糖部分，例如硫酸乙酰肝素糖胺聚糖（HSGAG）部分的方法和组合物。 还提供了用于促进或抑制胚胎干细胞分化（例如分化成内皮细胞）的方法和组合物。 因此，本发明还部分地涉及可以用所提供的方法和组合物产生的细胞群体（例如，内皮细胞群体或贫血的内皮细胞群体）。 此外，本发明部分地涉及通过所提供的方法和组合物形成的组织及其用途。 此外，本发明还部分涉及使用提供的方法和组合物的治疗方法。

    Nanocell Drug Delivery System
    5.
    发明申请
    Nanocell Drug Delivery System 审中-公开
    纳米细胞药物输送系统

    公开(公告)号：US20100303912A1

    公开(公告)日：2010-12-02

    申请号：US12780470

    申请日：2010-05-14

    申请人： Shiladitya Sengupta ,  Ganlin Zhao ,  Ishan Capila ,  David Eavarone ,  Ram Sasisekharan

    发明人： Shiladitya Sengupta ,  Ganlin Zhao ,  Ishan Capila ,  David Eavarone ,  Ram Sasisekharan

    IPC分类号： A61K9/14 ,  A61K31/765 ,  A61P35/00

    CPC分类号： A61K9/1271 ,  A61K9/0073 ,  A61K9/167 ,  A61K9/5153 ,  A61K31/09 ,  A61K31/7012 ,  A61K31/704 ,  A61K31/737 ,  A61K31/787 ,  A61K38/00 ,  A61K45/06 ,  A61K47/59 ,  A61K47/593 ,  A61K47/6907 ,  A61K47/6911 ,  A61K47/6925 ,  B82Y5/00 ,  B82Y10/00 ,  G01N33/5011 ,  G01N2500/10

    摘要： Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.

    摘要翻译： 纳米细胞允许以不同的作用方式或不同的药代动力学顺序递送两种不同的治疗剂。 通过在含有第二药剂的脂质囊泡内将第一药剂包封纳米孔而形成纳米细胞。 首先释放外部脂质隔室中的药剂，并在释放纳米孔内的药剂之前发挥其作用。 纳米细胞递送系统可以配制成药物组合物，用于递送患有疾病如癌症，炎性疾病如哮喘，自身免疫性疾病如类风湿性关节炎，感染性疾病和神经疾病如癫痫的患者。 在治疗癌症中，传统的抗肿瘤剂包含在纳米细胞的外脂质囊泡中，抗血管生成剂被加载到纳米孔中。 这种布置允许抗肿瘤药物首先释放并在肿瘤的血液供应被抗生血药剂切断之前被递送到肿瘤。

    Nanocell drug delivery system
    6.
    发明申请
    Nanocell drug delivery system 审中-公开
    纳米细胞药物递送系统

    公开(公告)号：US20070053845A1

    公开(公告)日：2007-03-08

    申请号：US11495947

    申请日：2006-07-28

    申请人： Shiladitya Sengupta ,  Ganlin Zhao ,  Ishan Capila ,  David Eavarone ,  Ram Sasisekharan

    发明人： Shiladitya Sengupta ,  Ganlin Zhao ,  Ishan Capila ,  David Eavarone ,  Ram Sasisekharan

    IPC分类号： A61K9/14 ,  A61L9/04

    CPC分类号： A61K9/5153 ,  A61K9/0073 ,  A61K9/127 ,  A61K9/1271 ,  A61K9/167 ,  A61K9/19 ,  A61K9/5031 ,  A61K9/5073 ,  A61K9/51 ,  A61K9/5123 ,  A61K31/09 ,  A61K31/7012 ,  A61K31/704 ,  A61K31/737 ,  A61K45/06 ,  A61K47/593 ,  A61K49/0043 ,  A61K49/0047 ,  A61K49/0093 ,  B82Y5/00 ,  B82Y10/00 ,  Y10T428/2982

    摘要： Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.

    摘要翻译： 纳米细胞允许以不同的作用方式或不同的药代动力学顺序递送两种不同的治疗剂。 通过在含有第二药剂的脂质囊泡内将第一药剂包封纳米孔而形成纳米细胞。 首先释放外部脂质隔室中的药剂，并在释放纳米孔内的药剂之前发挥其作用。 纳米细胞递送系统可以配制成药物组合物，用于递送患有疾病如癌症，炎性疾病如哮喘，自身免疫性疾病如类风湿性关节炎，感染性疾病和神经疾病如癫痫的患者。 在治疗癌症中，传统的抗肿瘤剂包含在纳米细胞的外脂质囊泡中，抗血管生成剂被加载到纳米孔中。 这种布置允许抗肿瘤药物首先释放并在肿瘤的血液供应被抗生血药剂切断之前被递送到肿瘤。

    Methods and products related to the improved analysis of carbohydrates
    7.
    发明授权
    Methods and products related to the improved analysis of carbohydrates 有权
    与碳水化合物改进分析有关的方法和产品

    公开(公告)号：US08000904B2

    公开(公告)日：2011-08-16

    申请号：US12574161

    申请日：2009-10-06

    申请人： Nishla Keiser ,  Carlos Bosques ,  Ram Sasisekharan ,  Pankaj Gandhe ,  Sasi Raguram ,  Aravind Srinivasan

    发明人： Nishla Keiser ,  Carlos Bosques ,  Ram Sasisekharan ,  Pankaj Gandhe ,  Sasi Raguram ,  Aravind Srinivasan

    IPC分类号： G01N31/00

    CPC分类号： G01N33/6842 ,  G01N33/6803 ,  G01N33/6851 ,  G01N2400/10 ,  Y10T436/143333

    摘要： The invention relates, in part, to the improved analysis of carbohydrates. In particular, the invention relates to the analysis of carbohydrates, such as N-glycans and O-glycans found on proteins. Improved methods, therefore, for the study of glycosylation patterns on cells, tissue and body fluids are also provided. Information regarding the analysis of glycans, such as the glycosylation patterns on cells, tissues and in body fluids, can be used in diagnostic and treatment methods as well as for facilitating the study of the effects of glycosylation/altered glycosylation on protein function. Such methods are also provided. Methods are also provided to assess protein production processes, to assess the purity of proteins produced, and to select proteins with the desired glycosylation.

    摘要翻译： 本发明部分涉及碳水化合物的改进分析。 特别地，本发明涉及对蛋白质上发现的碳水化合物如N-聚糖和O-聚糖的分析。 因此，还提供了改进的方法，用于研究细胞，组织和体液上的糖基化模式。 关于聚糖分析的信息，例如细胞，组织和体液中的糖基化模式，可用于诊断和治疗方法以及促进糖基化/改变糖基化对蛋白质功能的影响的研究。 还提供了这样的方法。 还提供了评估蛋白质生产过程，评估产生的蛋白质的纯度和选择具有所需糖基化的蛋白质的方法。

    METHODS AND PRODUCTS RELATED TO THE IMPROVED ANALYSIS OF CARBOHYDRATES
    8.
    发明申请
    METHODS AND PRODUCTS RELATED TO THE IMPROVED ANALYSIS OF CARBOHYDRATES 有权
    与改进的碳水化合物分析相关的方法和产品

    公开(公告)号：US20100144553A1

    公开(公告)日：2010-06-10

    申请号：US12623070

    申请日：2009-11-20

    申请人： Carlos Bosques ,  Nishla Keiser ,  Aravind Srinivasan ,  Rahul Raman ,  Karthik Viswanathan ,  Ram Sasisekharan ,  Pankaj Gandhe ,  Sasi Raguram

    发明人： Carlos Bosques ,  Nishla Keiser ,  Aravind Srinivasan ,  Rahul Raman ,  Karthik Viswanathan ,  Ram Sasisekharan ,  Pankaj Gandhe ,  Sasi Raguram

    IPC分类号： C40B40/12

    CPC分类号： G01N33/6851 ,  G01N33/66 ,  G01N33/68 ,  G01N33/6842 ,  G01N33/6848 ,  G01N2400/10 ,  G06F19/703

    摘要： The invention relates, in part, to the improved analysis of carbohydrates. In particular, the invention relates to the analysis of carbohydrates, such as N-glycans and O-glycans found on proteins and saccharides attached to lipids. Improved methods, therefore, for the study of glycosylation patterns on cells, tissue and body fluids are also provided. Information from the analysis of glycans, such as the glycosylation patterns on cells, tissues and in body fluids, can be used in diagnostic and treatment methods as well as for facilitating the study of the effects of glycosylation/altered glycosylation. Such methods are also provided. Methods are further provided to assess production processes, to assess the purity of samples containing glycoconjugates, and to select glycoconjugates with the desired glycosylation.

    摘要翻译： 本发明部分涉及碳水化合物的改进分析。 特别地，本发明涉及碳水化合物的分析，例如在蛋白质上发现的N-聚糖和O-聚糖以及与脂质连接的糖。 因此，还提供了改进的方法，用于研究细胞，组织和体液上的糖基化模式。 来自聚糖分析的信息，例如细胞，组织和体液中的糖基化模式，可用于诊断和治疗方法以及促进糖基化/改变糖基化作用的研究。 还提供了这样的方法。 进一步提供方法以评估生产过程，以评估含有糖缀合物的样品的纯度，并选择具有所需糖基化的糖缀合物。